Home›Companies›Biotech & Pharma›eGenesis

eGenesis, Inc.

Updated Oct 27, 2026·Latest SEC filing Feb 27, 2024·Suggest an edit

About eGenesis

eGenesis is a private company based in Cambridge, Massachusetts. It has reported $265,038,349 raised in five offerings on Form D since August 2016. Its chief executive is Michael Curtis.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Feb 13, 2024Feb 27, 2024$25,419,995of $28.7M target11$2.3MDebt, Securities on exerciseRule 506(b)Form D ↗
Feb 26, 2021Mar 10, 2021$124,999,955fully sold43$2.9MEquityRule 506(b)Form D ↗
Nov 1, 2019Nov 14, 2019$100,000,000fully sold20$5.0MEquityRule 506(b)Form D ↗
Mar 13, 2017Mar 23, 2017$12,618,399of $38.1M target12$1.0MEquityRule 506(c)Form D ↗
Aug 8, 2016Aug 23, 2016$2,000,000of $3.0M target2$1.0Mconvertible promissory notesRule 506(b)Form D ↗
Total, five offerings$265,038,349

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on eGenesis's Form D filed Feb 27, 2024.

Mark Pruzanski
Mark Pruzanski
Director
Also a chairman of the board at Abcuro.
BS
Brad Smith
Director
SG
RK
Rahul Kakkar
Director
AW
MC
Michael Curtis
President & CEO, director
JB
Jennifer Bergheiser
Executive officer
PS
Paul Sekhri
Director
LI

Earlier filings also listed Sapna Srivastava (executive officer, last listed Mar 2021), Peter Hanson (executive officer, last listed Mar 2021), Isaac Ciechanover (director, last listed Mar 2021), Kenneth Fan (executive officer, last listed Nov 2019), Juergen Eckhardt (director, last listed Nov 2019), Bob More (director, last listed Nov 2019), Ariel Jasie (executive officer, last listed Nov 2019) and Luhan Yang (president and director, last listed Mar 2017).

Sources

  1. SECeGenesis, Inc. filing history